(无)

This course, the Management and Risk Control of Drug Research and Development is to address economics that applies cost-benefit, cost-effectiveness, cost-minimization, and cost-utility analyses to evaluate the feasibility of drug R&D projects and to assess the economics of different pharmaceutical products or to compare drug therapy to other treatments. The primary purpose of the training in this discipline has been to provide assistance in making various healthcare decisions in the pharmaceutical industry. The rapid growth in the supply of pharmacoeconomic data over the past few years suggests that pharmacoeconomics can be of help in delivering good, cost-effective healthcare. Greater challenges in decision-making coupled with improvements in the techniques of pharmacoeconomic research point to a greater role for pharmacoeconomics in the coming years. This in turn will have consequences for companies in the pharmaceutical industry. More successful access to markets and better commercialisation of products will be the rewards for those companies committing to pharmacoeconomics and to the broader goal of delivering value for money in healthcare. In this 36 h course, the streamlines of drug research and development, the principles of pharmacoeconomics, statistics, as well as specific topics such as the research and development of chemical drugs and traditional Chinese medicines, etc, will be discussed. Students are anticipated to actively take part in the discussions and share their own perspectives in drug R&D with a view of improved management and risk control.